SummaryContiwin Co., Ltd is identified as a China-based trading company established in 2020, with a valid import/export license and an address in Shanghai. The available records show strong reported export orientation, more than 10 production lines, 31–40 quality-control staff, and stated output for hemodialyser flux and A-V blood lines; however, other records report only three total employees, creating an unresolved organizational inconsistency. Service logistics include stated peak- and off-season lead times within 15 workdays, multiple quotation and payment options, and prior participation in an international medical equipment trade show. The supplier reports no overseas warehouse, showroom, agent, branch, ODM, SDK, or popular-brand OEM capability. Quality assurance, traceability, certification, financial performance, customer cases, and several service-management controls are insufficiently documented. Complaint handling is explicitly unsupported by written procedures or records, and quality-control test...
Supplier typeThe supplier is identified as Contiwin Co., Ltd., a China-based trading company and limited company established in 2020, with Shanghai operations and no stated affiliation with a larger company group. It also reports a valid import/export license, supporting its trading and international-export role.
After-Sales capabilityThe supplier reports no written procedures or records for complaint handling, supplier-service assessment, or corrective and preventive actions. It has no overseas warehouse, showroom, agent, or branch, although it reports lead times within 15 workdays, participation in one offline trade show, and multiple quotation and payment options.
R&D capabilityThe supplier reports one R&D engineer whose stated responsibility is providing samples according to customer requirements. It also reports no new products in the past year, no ODM service, and no available SDK, indicating limited documented innovation capability.
Production capacityThe supplier reports more than 10 production lines, 31–40 quality-control staff, and stated annual output of 3,000,000 hemodialyser flux pieces and 10,000,000 A-V blood line sets. However, the separate record stating only three total employees creates a material inconsistency, while the reported zero quality-control test equipment weakens confidence in production-quality support.